CLINICAL TRIAL / NCT04502316

Inclusion Criteria: - Patients can be included in the registry if they were implanted with a de novo Barostim System. Patients must sign an informed consent form after implantation with the Barostim System in order to participate in the registry. Indications: The Barostim System is indicated for the improvement of symptoms of heart failure - quality of life, six-minute hall walk and functional status - for patients who remain symptomatic despite treatment with guideline-directed medical therapy, are NYHA Class III or Class II (who had a recent history of Class III), have a left ventricular ejection fraction ≤ 35%, a NT-proBNP < 1600 pg/ml and excluding patients indicated for Cardiac Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines. Contraindications: - Bilateral carotid bifurcations located above the level of the mandible - Baroreflex failure or autonomic neuropathy - Uncontrolled, symptomatic cardiac bradyarrhythmias - Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50% - Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation - Known allergy to silicone or titanium